Levsin (Hyoscyamine) Is Not Recommended for Abdominal Pain from Pancreatitis or Gastroparesis
Levsin (hyoscyamine) should not be used for abdominal pain caused by pancreatitis or gastroparesis. While the FDA approves hyoscyamine for various gastrointestinal conditions, neither pancreatitis nor gastroparesis are among the indicated uses, and current evidence-based guidelines do not support its use for these conditions 1.
Why Hyoscyamine Is Not Appropriate
For Gastroparesis
The 2025 AGA Clinical Practice Guideline on Management of Gastroparesis provides clear, evidence-based treatment algorithms and does not include anticholinergic/antispasmodic agents like hyoscyamine 2. This is a critical omission because:
- Anticholinergics can worsen gastroparesis by further slowing gastric emptying through their antimuscarinic effects on GI smooth muscle
- The guideline emphasizes that clinicians should "eliminate medications that may alter GI tract motility" 2
- When abdominal pain is the predominant symptom in gastroparesis, the guideline specifically recommends ruling out alternative causes and considering agents like nortriptyline (a neuromodulator) rather than antispasmodics 2
The recommended first-line pharmacologic treatments for gastroparesis are metoclopramide or erythromycin 2, both of which are prokinetic agents that enhance gastric emptying—the opposite mechanism of hyoscyamine.
For Pancreatitis
Neither acute nor chronic pancreatitis guidelines recommend antispasmodic agents for pain management 3, 4, 5, 6. The 2022 AGA Clinical Practice Update on pancreatitis does not mention hyoscyamine or similar anticholinergics as treatment options 3. Pain management in pancreatitis typically involves:
- Analgesics (NSAIDs, opioids when necessary)
- Treatment of underlying causes
- Endoscopic or surgical interventions for refractory cases
- Pancreatic enzyme supplementation for chronic pancreatitis
FDA-Approved Indications for Levsin
According to the FDA label, hyoscyamine is indicated for 1:
- Peptic ulcer disease (adjunctive therapy)
- Irritable bowel syndrome
- Spastic colitis
- Functional intestinal disorders
- Biliary and renal colic (with narcotics)
Notably absent: gastroparesis and pancreatitis
Evidence on Antispasmodics
While hyoscyamine has been studied for irritable bowel syndrome and functional GI disorders, the evidence is limited. A 2021 review found that dicyclomine and hyoscyamine have not been proven effective in reducing abdominal pain in IBS patients 7, 8. Even in conditions where antispasmodics might theoretically help, the evidence is weak or contradictory.
Common Pitfalls to Avoid
- Do not confuse "GI spasm" with gastroparesis: Gastroparesis is a motility disorder requiring prokinetic therapy, not antispasmodics that further reduce motility
- Abdominal pain alone is not an indication: When gastroparesis patients have predominant abdominal pain, consider alternative diagnoses (functional dyspepsia, chronic pain syndromes) and use neuromodulators like nortriptyline 2
- Anticholinergic side effects can worsen symptoms: Hyoscyamine causes constipation, bloating, and abdominal pain as adverse effects 1—symptoms that overlap with gastroparesis complaints
What to Use Instead
For Gastroparesis with Abdominal Pain:
- First: Optimize glycemic control, eliminate motility-altering medications, implement dietary modifications (small-particle, low-fat, low-residue diet) 2
- Pharmacologic: Metoclopramide (5-10 mg before meals) or erythromycin (40-250 mg daily) 2
- For predominant pain: Consider nortriptyline as a neuromodulator 2
- Antiemetics as needed: 5-HT3 antagonists (ondansetron), H1 antagonists (promethazine), or D2 antagonists (prochlorperazine) 2